| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Chloropyridine-3-boronic acid does not have a defined primary pharmacological target as it is primarily a chemical reagent and synthetic intermediate. In medicinal chemistry, the compound serves as a key building block for constructing pyridine-containing drug candidates. The boronic acid functionality enables Suzuki-Miyaura cross-coupling reactions with various aryl and heteroaryl halides, allowing for the synthesis of biaryl and heterobiaryl compounds that are common structural motifs in pharmaceuticals. The chlorine atom provides an additional handle for further functionalization through nucleophilic aromatic substitution or cross-coupling reactions. The pyridine ring can engage in hydrogen bonding and π-π interactions with biological targets.
|
|---|---|
| ln Vitro |
In vitro activity of 2-Chloropyridine-3-boronic acid as a standalone compound is not typically evaluated, as its primary role is as a synthetic intermediate. The compound's biological activity would be assessed through the final drug molecules synthesized from this building block. In biochemical research, the compound may be used as a reference or as a starting material for generating compound libraries. Its utility in synthesizing ethyl canthinone-3-carboxylates and other complex molecules suggests that derivatives of this compound may possess various biological activities depending on the final structures constructed.
|
| ln Vivo |
In vivo activity data for 2-Chloropyridine-3-boronic acid are not available, as the compound is not intended for direct administration as a therapeutic agent. It is classified as a biochemical reagent and organic synthesis intermediate. Any in vivo effects would be associated with the final drug products synthesized from this intermediate rather than the compound itself. The compound's role in drug discovery is to enable the synthesis of complex molecular scaffolds that can be evaluated in animal models of disease. Researchers handling this compound should follow appropriate safety protocols for chemical handling in laboratory settings.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for 2-Chloropyridine-3-boronic acid are not standard, as the compound is a chemical reagent rather than a drug candidate. If evaluated as a potential ligand, typical binding assays might involve radioligand displacement or surface plasmon resonance techniques. For enzyme inhibition studies, purified enzyme is incubated with varying concentrations of the compound in appropriate buffer systems. However, such studies are more commonly performed on the final pharmaceutical compounds derived from this building block rather than on the intermediate itself. The compound may serve as a reference or control in certain biochemical experiments.
|
| Cell Assay |
Cell-based in vitro experiments using 2-Chloropyridine-3-boronic acid are not typically performed, as the compound is a research chemical and synthetic intermediate. When used in cell biology research, the compound might be incorporated into larger molecules that are then tested on cultured cell lines. Standard cell culture protocols would involve seeding cells in appropriate media at 37°C in a 5% CO₂ atmosphere, treating with test compounds at various concentrations, and assessing cell viability, proliferation, or other endpoints using standard assays. The compound's solvent compatibility (typically DMSO) and potential cytotoxicity should be considered.
|
| Animal Protocol |
In vivo animal studies are not conducted with 2-Chloropyridine-3-boronic acid itself, as it is a chemical reagent rather than a therapeutic agent. The compound is utilized in the synthesis of drug candidates that may subsequently be evaluated in animal models. Typical in vivo protocols for drug candidates synthesized from this building block would involve administration via oral gavage, intravenous injection, or intraperitoneal injection to rodents at various dose levels. Pharmacodynamic endpoints, pharmacokinetic sampling, and toxicological assessments would be performed according to the specific research objectives. All animal studies must be conducted in accordance with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Chloropyridine-3-boronic acid have not been characterized, as the compound is a chemical reagent for research use. As a small heterocyclic molecule with molecular weight 157.36 g/mol, it would be expected to have moderate aqueous solubility. Boronic acids are generally susceptible to oxidative degradation and may undergo metabolism via deboronation. The chlorine atom and pyridine ring would influence metabolic pathways. The compound's LogP is estimated to be around 1.0–1.5, indicating moderate hydrophilicity. However, these properties are not studied for the compound itself, as it is not developed as a pharmaceutical. For drug discovery applications, the pharmacokinetic profile would be optimized at the final drug candidate stage.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Chloropyridine-3-boronic acid are limited, as the compound is handled as a research chemical in laboratory environments. Standard safety precautions should be followed, including the use of appropriate personal protective equipment such as gloves, goggles, and lab coats. The compound may cause irritation to skin, eyes, and respiratory tract upon exposure. Inhalation of dust should be avoided, and adequate ventilation should be ensured when handling the compound. Boronic acid derivatives should be handled with care due to potential reactivity. In case of contact, affected areas should be rinsed with plenty of water. The compound should be stored in a cool, dry place away from strong oxidizing agents and moisture. Comprehensive toxicological studies have not been reported.
|
| Additional Infomation |
2-Chloropyridine-3-boronic acid is a chemical research tool and synthetic intermediate rather than an approved pharmaceutical drug. Its primary applications are in organic synthesis and drug discovery, where it serves as a versatile building block for Suzuki-Miyaura cross-coupling reactions and other transformations. The compound has been utilized in the synthesis of ethyl canthinone-3-carboxylates and other complex heterocyclic compounds. The boronic acid functionality enables the construction of biaryl and heterobiaryl compounds, which are common structural motifs in numerous pharmaceuticals. No clinical trials or regulatory approvals have been documented for this compound as a therapeutic agent. The compound is commercially available as a research-grade chemical with purity typically 96% or higher, supplied for laboratory synthesis and biochemical research.
|
| Molecular Formula |
C5H5BCLNO2
|
|---|---|
| Molecular Weight |
157.36
|
| Exact Mass |
157.01
|
| CAS # |
381248-04-0
|
| PubChem CID |
2762704
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
349.3±52.0 °C at 760 mmHg
|
| Melting Point |
160°C
|
| Flash Point |
165.1±30.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
0.77
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
114
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=NC=CC=C1B(O)O
|
| InChi Key |
VRDAOVQZVXYRNH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5BClNO2/c7-5-4(6(9)10)2-1-3-8-5/h1-3,9-10H
|
| Chemical Name |
(2-chloropyridin-3-yl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.3549 mL | 31.7743 mL | 63.5486 mL | |
| 5 mM | 1.2710 mL | 6.3549 mL | 12.7097 mL | |
| 10 mM | 0.6355 mL | 3.1774 mL | 6.3549 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
